SITC 2023 | Next steps in validating glycosylated proteins as biomarkers for melanoma treatment response

Yana Najjar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, outlines next steps in the development of glycosylated proteins as a predictive biomarker for immunotherapy response in metastatic myeloma. Whilst they have generated a robust signal, this needs to be validated in a larger, independent (and ideally multi-institutional) cohort. Additionally, prospective validation of these biomarkers would need to take place for them to be truly predictive. Dr Najjar identifies questions for the future concerning the scalability of the LCMS AI system used in this approach and its potential clinical benefits in tailoring therapy to specific patients’ needs. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.